Upstream Bio (UPB) Capital Expenditures (2024 - 2025)
Upstream Bio's quarterly Capital Expenditures came in at $110000.0 in Q4 2025, down 70.9% year-on-year from $378000.0 in Q4 2024, and up 1275.0% quarter-over-quarter from $8000.0 in Q3 2025.
Upstream Bio has reported Capital Expenditures for 2 years, with the latest figure at $110000.0 in Q4 2025.
- For the quarter ending Q4 2025, Capital Expenditures fell 70.9% year-over-year to $110000.0; the trailing twelve-month figure through Dec 2025 stood at $496000.0 (changed N/A YoY), and the FY2025 full-year result was $165000.0, down 67.71% from the prior year.
- Capital Expenditures for Q4 2025 stood at $110000.0, up from $8000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $378000.0 in Q4 2024, with the low at $8000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 110,000.00 |
| Dec 31, 2025 | 110,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Dec 31, 2024 | 378,000.00 |
| Dec 31, 2024 | 378,000.00 |